2023-07-10 17:43:44
New Guideline Released on Overweight and Obesity in Adults
A new guideline titled ‘Overweight and obesity in adults’ has been made available, focusing on the care-related aspects of these health conditions. The guideline outlines the roles and responsibilities of different care providers in a comprehensive care standard. One of the organizations involved in the development of this multidisciplinary guideline is the Royal Dutch Pharmacists Association (KNMP).
One of the key areas covered in the guideline is pharmacotherapy for overweight and obesity in adults. The guideline recommends considering weight-reducing medication for individuals with obesity or severe overweight, particularly if they have an increased abdominal circumference and/or comorbidities. According to the guideline, medications such as liraglutide, semaglutide, and naltrexone/bupropion have shown to be more effective than orlistat. However, the use of naltrexone/bupropion is not recommended for individuals at risk of convulsions or those with psychiatric or addiction problems. In cases where weight loss is less than 5% after 12 weeks of maximum tolerated medication dose, orlistat, liraglutide, and naltrexone/bupropion should be discontinued. However, if there are clear improvements in body composition and comorbidities, the trial period with medication can be extended.
The guideline also highlights the opportunities for regional cooperation among pharmacists in implementing the recommendations. For instance, pharmacists can use the guideline as a basis for discussion with other healthcare providers, such as in a formal transfer of care (FTO) meeting. Pharmacists play a crucial role in medication monitoring for patients with morbid obesity and those who have undergone bariatric surgery, as the pharmacokinetics and drug dynamics may be altered in these patient groups. The guideline emphasizes the importance of documenting and exchanging contraindication information, as well as conducting medication reviews prior to bariatric surgery to ensure appropriate medication adjustment.
The Scientific Section of Community Pharmacists (WSO) believes that the arrival of this guideline presents an opportunity for pharmacists to enhance their involvement in providing care for obese patients and those who have undergone bariatric surgery. The pharmacist’s contribution may include ideas for choosing weight-reducing medication and conducting medication reviews to identify potential weight-increasing medications or movement-impairing factors.
The KNMP is providing support in the care of obese patients and those who have undergone bariatric surgery. The Morbid Obesity and Bariatric Surgery dossier on KNMP.nl offers a wealth of resources, including a knowledge document, practical examples, articles, and public materials.
With the availability of this new guideline, healthcare professionals hope for improved care and outcomes for individuals struggling with overweight and obesity. By following the guideline’s recommendations and collaborating effectively, care providers can work towards reducing the burden of these conditions and improving overall health and well-being.]
#guideline #Overweight #obesity #adults